Loading organizations...
Altus Pharmaceuticals was a Waltham, Massachusetts-based biopharmaceutical company that developed novel oral and injectable protein therapeutics for chronic gastrointestinal and metabolic diseases. The organization utilized proprietary crystallization technology to create highly stable protein replacement therapies, primarily focusing on treatments for severe conditions such as cystic fibrosis and growth hormone deficiency. Operating as a pre-revenue clinical research enterprise under the leadership of former chief executive officer Georges Gemayel, the company raised $50 million during its 2006 initial public offering and secured an additional $20 million in a 2007 funding round. Before ceasing operations in 2009 due to broader macroeconomic constraints, the firm collaborated closely with the Cystic Fibrosis Foundation Therapeutics and transferred its remaining drug assets to Alnara Pharmaceuticals. Originally established as a strategic corporate spin-out from Vertex Pharmaceuticals, the biotechnology company was founded in 1992.
Altus Pharmaceuticals has raised $102.0M across 2 funding rounds.
Altus Pharmaceuticals has raised $102.0M in total across 2 funding rounds.
Altus Pharmaceuticals has raised $102.0M across 2 funding rounds. Most recently, it raised $51.0M Series C in May 2004.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2004 | $51M Series C | — | Deerfield Management, U.S. Venture Partners | Announced |
| Oct 1, 2001 | $51M Series B | — | U.S. Venture Partners | Announced |
Altus Pharmaceuticals Inc. was a US-based biopharmaceutical company founded in 1992 and headquartered in Waltham, MA, focused on developing enzyme-based therapeutics and drug delivery technologies.[5][6] It is now out of business, having shuttered operations in October 2009 after delisting from public trading and settling debts with Vertex Pharmaceuticals.[5][6] The company participated in SBIR programs but ultimately ceased activities, with no current products or ongoing clinical trials directly attributable to it in recent records.[6]
Note that multiple entities share similar names: a Zambian distributor (Altus Pharmaceuticals Ltd) imports pharmaceuticals and medical supplies to improve community healthcare access[2]; Altus Drug Development creates value-added medicines using patented drug delivery tech for partners[3][4]; and Altus Pharmaceuticals within Provider Network Holdings provides supply chain services for specialty drugs, supporting 1,500+ physicians.[1] This analysis centers on the original Altus Pharmaceuticals Inc. as the primary match for a technology-driven pharma company, given its innovation history.
Altus Pharmaceuticals Inc. was founded in 1992 in Waltham, MA, initially pursuing enzyme therapeutics and advanced drug formulation technologies.[5][6] Key details on founders are not specified in available records, but the company gained traction through government SBIR funding for biotech innovations and public trading status before facing financial challenges.[6] A pivotal moment came in October 2009 when it voluntarily delisted, settled debts via a deal with Vertex Pharmaceuticals, and shut down operations, marking the end of its journey.[6]
These elements set it apart in the competitive enzyme therapeutics space, though its out-of-business status limits ongoing differentiation.[5]
Altus Pharmaceuticals rode the 1990s-2000s biotech boom in enzyme stabilization and targeted drug delivery, addressing challenges in protein therapeutics stability—a key hurdle for biologics before modern platforms like mRNA emerged.[5][6] Timing aligned with rising interest in outsourced R&D via SBIR, influencing early ecosystem funding for similar firms, but market forces like funding droughts contributed to its 2009 closure amid biotech sector volatility.[6] Its shuttering underscores risks in pre-commercial biopharma, paving the way for survivors like Vertex to consolidate assets and advance the field.
With operations ended since 2009, Altus Pharmaceuticals Inc. has no active future; its technologies likely absorbed via partnerships like Vertex, contributing indirectly to modern drug delivery advances.[6] Trends in value-added formulations—seen in active namesakes like Altus Drug Development—suggest enduring demand for such innovations amid $300B+ specialty drug markets.[1][3][4] Its legacy warns of biopharma pitfalls while highlighting how defunct pioneers fuel ecosystem evolution, tying back to its original mission of tech-driven therapeutics.
Altus Pharmaceuticals has raised $102.0M in total across 2 funding rounds.
Altus Pharmaceuticals's investors include Deerfield Management, U.S. Venture Partners.
